SUPERNUS PHARMACEUTICALS, INC. (SUPN) FY2026 YTD Q2 P&L / Income Statement

SUPERNUS PHARMACEUTICALS, INC. (SUPN) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service (3 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

426,763,000 US dollars

Cost of revenues

57,060,000 US dollars

Gross profit (calculated)

369,703,000 US dollars

Operating expenses (calculated)

435,998,000 US dollars

Operating earnings (loss)

negative 66,295,000 US dollars

Total other income, net

2,697,000 US dollars

Earnings (loss) before income taxes

negative 63,598,000 US dollars

Income tax expense (benefit)

negative 2,934,000 US dollars

Net earnings (loss)

negative 60,664,000 US dollars

Net product sales

316,466,000 US dollars

Collaboration revenue (ZURZUVAE)

62,993,000 US dollars

Royalty, licensing, and other revenues

47,304,000 US dollars

Research and development

68,901,000 US dollars

Selling, general and administrative

258,810,000 US dollars

Amortization of intangible assets

50,977,000 US dollars

Intangible asset impairment charges

54,919,000 US dollars

Contingent consideration loss

2,391,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.